Cellular Medicines for Inflammatory Conditions

Mesoblast is using its proprietary technology platform to develop and commercialize innovative cellular medicines to treat complex diseases in which inflammation plays a central role and are resistant to conventional standard of care.

Its broad portfolio of late-stage product candidates comprises three product candidates in Phase 3 development – remestemcel-L for acute graft versus host disease, Revascor for advanced heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. Additionally, Mesoblast has a promising emerging pipeline of Phase 2 product candidates and next generation technologies.

Mesoblast has initiated a rolling Biologics License Application to the United States Food and Drug Administration (FDA) for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease. Its patented technology platform has been validated by the first approvals of an allogeneic cellular medicine by its licensees in Japan and Europe.

Innovative technology platform

Mesoblast’s novel allogeneic product candidates are based on rare (approximately 1:100,000 in bone marrow) mesenchymal lineage cells that respond to tissue damage, secreting mediators that promote tissue repair and modulate immune responses. 

Mesenchymal lineage cells are collected from the bone marrow of healthy adult donors and proprietary processes are utilized to expand them to a uniform, well characterized, and highly reproducible cell population. This enables manufacturing at industrial scale for commercial purposes.  Another key feature of Mesoblast’s cells is they can be administered to patients without the need for donor–recipient matching or recipient immune suppression, and therefore are often referred to as ‘off-the-shelf’ cellular medicines.